Sickle cell disease

Sickle cell disease

WHO / Yoshi Shimizu

Sickle cell disease (SCD) is a common inherited haemoglobin disorder affecting an estimated 7.74 million people worldwide1, with nearly half the global burden estimated to be in Nigeria, the Democratic Republic of the Congo and India.2 3Nearly half a million babies are born each year with SCD, about 90% in low- and middle-income countries. Estimates from the 2021 Global Burden of Disease Study indicate that the number of people living with SCD rose by 41%, from 5.46 million in 2000 to 7.74 million in 2021. In 2021, an estimated 34 400 deaths across all age groups were directly attributed to SCD globally, while overall SCD associated mortality burden across all age groups was estimated at at 376 000 deaths, nearly 11-fold higher.

Despite this substantial and growing burden, SCD remains neglected, with marked inequalities in access to early diagnosis, treatment and comprehensive care. Hydroxyurea is the first-line disease-modifying therapy in high-income countries and has demonstrated efficacy among children and adults in low-resource settings, but access remains limited in many low- and middle-income countries. WHO guidelines strongly recommend hydroxyurea for children and adolescents aged nine months to 19 years with sickle cell anaemia (HbSS and HbSβ0-thalassaemia), regardless of clinical severity, and emphasise appropriate paediatric formulations.

A major price reduction for a quality-assured 500 mg capsule was announced in June 2025 for low- and middle-income countries. However, this formulation is unsuitable for young children because of limited dose flexibility and poor acceptability. Lower-strength capsules, tablets that can be dispersed in water and oral suspensions remain inconsistently available or suboptimal.

To address these gaps, the WHO Paediatric Drug Optimization exercise for sickle cell disease (PADO-SCD) reviewed available hydroxyurea formulations and identified priority characteristics for age-appropriate products, informing the development of a target product profile (TPP) to guide manufacturers towards formulations suitable for flexible weight-based dosing and use in resource-limited settings. This work subsequently informed WHO's first invitation to manufacturers to submit expressions of interest for prequalification of SCD therapeutics, including paediatric-friendly hydroxyurea formulations. L-glutamine and crizanlizumab have received regulatory approval in some jurisdictions but are not currently recommended by WHO. Neither was prioritized by PADO-SCD, which identified the need for further evidence to clarify their potential role in the treatment of children with SCD.

The PADO-SCD exercise also reviewed existing and emerging therapies, identifying promising compounds and priority research areas to guide and accelerate future paediatric development. Gene-based therapies are also under development, although cost, complexity and infrastructure requirements challenge equitable access.

Portfolio products

5 products · PADO-sickle cell disease, 2026
● Access list: 0    ● Priority list: 1    ● Watch list: 4
0 Access
1 Priority
4 Watch

PADO-SCD priority list 1
Hydroxyurea
500 mg single-scored soluble or single-scored dispersible tablets (optimal and minimum)
100 mg single-scored soluble or single-scored dispersible tablets (optimal)
PADO-SCD watch list 4
Mitapivat
Etavopivat
Tebapivat
Decitabine + tetrahydrouridine (Ndec)

PADO report

Paediatric drug optimization for sickle cell disease: meeting report, 8-10 September 2025
This meeting report describes the priority-setting process and summarizes the consensus reached by participants on therapeutic priorities for paediatric...

Contact

Wilson Were
Email: werew@who.int

Nuhu Yaqub
Email: yaqubn@who.int